GENENTECH USA, INC.

LUNSUMIO

Manufacturer:

GENENTECH USA, INC.

Lunsumio HCPCS:

J9350

HCPCS Code Descriptor:

Injection, mosunetuzumab-axgb, 1 mg

Category:

J Code

Lunsumio NDCs:

50242-0142-01, 50242-0159-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Lunsumio:

LUNSUMIO is a Oncology drug manufactured by GENENTECH USA, INC. and administered via the Intravenous route of administration. The J Code: J9350 is aligned to the drug LUNSUMIO.

LUNSUMIO is an anti-cancer medication that belongs to the drug classes B-cell lymphoma inhibitor and anti-CD20 monoclonal antibodies. This medication can be used to treat a specific cancer of the lymphatic system. It works by targeting B lymphocytes (B cells) and targeting the CD20 protein on the B cells and the CD3 protein on the T cells. LUNSUMIO is manufactured by Genentech USA and is aligned to the HCPCS code J9350. Patient assistance programs for this medication can be found through the Genentech Patient Foundation.

ACCESS PRICING AND MORE BY REGISTERING

J9350 Added Date:

July 1, 2023

J9350 Effective Date:

July 1, 2023

J9350 Termination Date:

HCPCS Active

Lunsumio billing and coding information can be found through Genentech Usa, Inc. at the link below:
Lunsumio patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
LUNSUMIO prescribing information can be found at the link below:
Information regarding LUNSUMIO’s side effects can be found at MedlinePlus